Zuellig Pharma has announced the acquisition of all rights, title, and interest in and to the Zam-Buk® and Vapex® consumer healthcare brands from Bayer Consumer Care AG for Thailand, Singapore, Indonesia, Malaysia, and Brunei.
Zam-Buk® is an ointment used for the temporary relief of pain and itch, including discomfort from insect bites. First launched in 1902, Zam-Buk® has retained strong brand equity over the decades and is widely perceived as a trusted household brand. Vapex® is a nasal inhaler used to help relieve nasal congestion. Launched in 1917, Vapex® has built meaningful brand recognition, particularly in Thailand.
The acquisition marks a strategic move by Zuellig Pharma to expand its consumer healthcare portfolio with well-established and trusted heritage brands. This marks the company’s second consumer healthcare acquisition, following Propan in the Philippines, reflecting its focus on building a strong commercial platform for trusted, everyday healthcare products in the region.
John A. Graham, CEO of Zuellig Pharma, commented on the acquisition, “This acquisition marks another significant growth milestone for our consumer healthcare product portfolio. Zam-Buk® and Vapex® are enduring brands with deep heritage and trust in the communities they serve. By combining the brands’ legacy with Zuellig Pharma’s regional commercial capabilities and local market expertise, we aim to expand distribution and access across all relevant retail channels in the region. In doing so, these brands will continue to remain relevant, easy to find, and accessible to consumers.”
Through this transaction, Zuellig Pharma aims to enhance its regional consumer health offerings while leveraging its robust distribution network, commercial expertise, and market presence.
